By the early 1990s several independent studies indicated IFN-α as an efficient anti-tumor drug in HIV patients with Kaposi’s sarcoma who had CD4 counts higher than 200 cells/mm3 (reviewed in [61]). Here, IFNA2 is linked to Kaposi's sarcoma.